Psoriasis treatment device developer Luma Therapeutics raised $2 million in a new round of equity financing, according to an SEC filing posted this week.
The company is developing the Luma Therapeutics System, designed to treat psoriasis through a “combination of modalities,” according to its website. The system aims to be “fast, simple and affordable” and usable by patients at home.
The company said the device will “modernize” the Goeckerman treatment for psoriasis, which includes coating affected skin with coal tar, occluding the skin and treating it with UV-B light, according to its website.
Luma Therapeutics is seeking another $562,662 in the round, thought it has not yet stated how it plans to spend funds raised so far.
Money in the round has come from 17 unnamed investors, according to the SEC filing, with the 1st sale registered on Feb. 6.